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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Background of Study 
 
Cancer which is commonly characterized by uncontrolled cell growth caused by 
up regulation of oncogenes or down regulation of tumour suppressor genes and 
angiogenesis is one of the leading causes of death worldwide (Siegel et al., 2015). 
Molecular subtypes of breast cancer included luminal A, luminal B, basal-like breast 
cancer, triple negative breast cancer (TNBC) and epidermal growth factor receptor 2 
(HER2) positive breast cancer (Nounou et al., 2015). Breast cancer generally classified 
based on tumour markers of progesterone receptor (PR), estrogen receptor (ER) and 
HER2 (Parise and Caggiano, 2014). However, TNBC lack of these three receptor proteins 
(PR- / ER- / HER2-). TNBC subgroup comprise approximately 15% of all types of breast 
cancer with a significantly higher percentage found in younger women. In a cohort study 
of 1601 breast cancer patients, mean age of women diagnosed with TNBC was 53 years 
whereas patients with other subtypes was 58 years (Cleator et al., 2007; Bartsch et al., 
2010). The incidence of TNBC cases in Malaysia is approximately 17%, a rate similar to 
that found in Western studies (Dean and Rhodes, 2014). 
 
Treatment options currently available for TNBC are limited to standard 
cytotoxicity chemotherapy such as paclitaxel due to the lack of therapeutic target required 
to effectively deliver drugs to tumour with minimal by-effect on healthy cells and 
multidrug resistance (MDR) exhibited by TNBC tumour that prevents delivery of 
therapeutic agents into tumours (Pal et al., 2012; O’Reilly et al., 2015). However, 
nanomedicine offers effective solutions to overcome the problems encountered by 
conventional chemotherapy. Nanomedicine able to deliver therapeutic agents into the 
targeted cells via receptor-mediated endocytosis (RME) in addition nanocarriers able to 
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conquer MDR by providing protection to therapeutic agents and prevent elimination of 
P-glycoproteins (P-gp) (Kutty, 2015). Issues with conventional chemotherapy such as 
drug resistance, formulation and pharmacokinetics (controlled drug release) may be 
solved with the assist of nanomedicine.  
 
Patients with TNBC are usually detected at the late stage, have an aggressive 
tumour type due to high rate of local recurrences and systematic metastases and a poorer 
prognosis compared to patients with non-TNBC (Cao et al., 2010). In addition, the mean 
time to local and distant recurrence were shorter in patients with TNBC than other cancers 
which were 2.8 versus 4.2 years and 2.6 versus 5.0 years respectively (Dent et al., 2007). 
These patients were significantly more likely to have visceral metastases, which might 
contribute to their poorer prognosis. Hence, there is a clear demand to examine 
nanotheranostics for sensitive diagnosis at its earliest stage and effective therapy act on 
TNBC tumour by therapeutic agent. 
 
The aim of this study is to develop and characterize a novel theranostic micelle 
system for TNBC treatment. Docetaxel is chosen as the model anticancer agent or 
therapeutic agent whereas coumarin-6 is chosen as the diagnostics or imaging agent and 
both are encapsulate by D-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E 
TPGS/TPGS) which act as the nanocarrier to deliver the chemotherapeutic agent and 
diagnostic agent into TNBC cells. Docetaxel leads to mitotic arrest in the G2/M phase of 
cell cycle by binding to microtubules and causes cell death (Kutty, 2015). Coumarin-6 
with fluorescence property is able to act as fluorescent probe for applications such as 
biomarker and bioimaging to visualize morphological details and monitor biomolecule in 
living systems (Chen et al., 2013). Vitamin E consist of both lipophilic alkyl tails and 
hydrophilic polar heads was used to synthesize the polymeric micelle which above its 
critical micelle concentration (CMC) of 0.02 wt%. It is hypothesized that the theranostic 
micelle system will be able to synthesize with higher drug loading within the expected 
micelle size. 
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1.2 Motivation 
 
Coumain-6 with great fluorescence imaging capacity can serve as a powerful and 
promising candidate for bioimaging probe which required for early diagnosis of cancer 
in order to be treated efficiently with therapeutic drugs. There is higher chance to be 
treated efficiently if cancer is able to diagnose at an early stage as treatment becomes 
more difficult if the cancer cell has spread and generally lower chance of surviving.  
 
The co-delivery of both chemotherapeutic agent and diagnosis agent in a dual 
modality micelle system form a theranostic nanoparticle that can be used in the diagnosis 
and therapy on cancer cell in early stage which can control local recurrences and prevent 
distant metastases. 
 
 
1.3 Problem statement 
 
TNBC is one of the most aggressive cancer due to its higher rate of local 
recurrences and distant metastases. TNBC represents a challenge for clinicians due to its 
poorer prognosis in comparison to other breast cancer subtypes and fewer treatment 
options, with a lack of targeted therapy for effective delivery of chemotherapeutic agents 
into metastasised TNBC cells (Wahba and El-Hadaad, 2015). Cancerous cells tend to 
develop MDS which is a major factor in the failure of many forms of chemotherapy 
(Kutty, 2015). Therefore, we postulated a novel polymer-based nanocarrier for the co-
delivery of fluorescence imaging agent (coumarin-6) and chemotherapeutic drug 
(docetaxel) in order to develop the tumour-imaging for early cancer detection, thereby 
having efficiency therapy in early stage in addition inhibit MDS and reducing the rate of 
recurrence and metastasis. 
